8. Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclini- cal species.Eur J Pharm Sci. 2017;104:31-41. 9. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglu- tide, a once-weekly human GLP-1 analog, does not reduce the bio- availability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55:497-504. 10. Sorli C, Harashima S, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251-260. 11. Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once weekly semaglutide versus sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with type 2 diabetes (SUSTAIN 2): a 56-week randomised, controlled clinical trial.Lancet Diabetes Endocri- nol. 2017;5:341-354. 12. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-na√Øve subjects with type 2 diabetes (SUSTAIN 4): a rando- mised open-label clinical trial.Lancet Diabetes Endocrinol . 2017;5: 355-366. 13. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2016;375: 1834-1844.